Aridis Pharmaceuticals (ARDS) News Today → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free ARDS Stock Alerts $0.06 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAridis Pharmaceuticals Inc (ARDS)uk.investing.com - March 14 at 9:53 AMIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protestbbc.co.uk - February 10 at 7:59 PMAridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024finance.yahoo.com - December 15 at 9:07 PMAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Updatemarkets.businessinsider.com - November 3 at 5:11 PMAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Updatefinance.yahoo.com - November 3 at 5:11 PMAridis Pharmaceuticals Inc ARDSmorningstar.com - November 1 at 4:04 PMAridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, Predictionsbenzinga.com - October 22 at 1:46 PMHC Wainwright & Co. Maintains Aridis Pharmaceuticals (ARDS) Buy Recommendationmsn.com - October 21 at 1:44 PMFDA’s Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals’ Investment Appeal: An Analyst’s Buy Recommendationmarkets.businessinsider.com - October 20 at 2:15 PMARDS Sep 2023 2.500 callfinance.yahoo.com - September 15 at 7:41 PMAridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TVfinance.yahoo.com - September 15 at 9:40 AMAridis Pharma (ARDS) Earnings Dates & Reportsinvesting.com - August 21 at 10:59 PMAridis Pharmaceuticals Announces $2 Million Offeringfinance.yahoo.com - August 2 at 9:42 AMWhy Are Aridis Pharmaceuticals Shares Moving Higher Today?finance.yahoo.com - July 18 at 3:12 PMAridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301finance.yahoo.com - July 17 at 6:32 PMAridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301finance.yahoo.com - July 13 at 2:44 PMAridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designationfinance.yahoo.com - July 12 at 2:04 PMAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)marketwatch.com - June 22 at 5:22 PMAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)finance.yahoo.com - June 20 at 12:47 PMAridis Pharmaceuticals, Inc.: Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Updatefinanznachrichten.de - June 9 at 9:37 AMAridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Updatefinance.yahoo.com - June 8 at 6:27 PMAridis Pharmaceuticals Stock (NASDAQ:ARDS), Guidance and Forecastbenzinga.com - June 1 at 5:15 PMAridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Designfinance.yahoo.com - May 31 at 10:51 AMAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Qfinance.yahoo.com - May 25 at 4:32 PMAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Kfinance.yahoo.com - April 26 at 1:56 PMBig pharma, small drug maker spar over pneumonia drug dealbizjournals.com - April 3 at 2:04 PMAridis Provides Corporate Updatefinance.yahoo.com - March 31 at 8:13 PMAstraZeneca Axes Pneumonia Drug Pact With Aridismsn.com - March 29 at 4:37 PMWhy Aridis Pharmaceuticals Shares Are Divingmsn.com - March 14 at 5:54 PMAridis Pharmaceuticals Shares Tumble After Stock Offering >ARDSmarketwatch.com - March 14 at 5:54 PMAridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goalsmsn.com - March 14 at 5:54 PMAridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stockfinance.yahoo.com - March 14 at 5:54 PMAridis Skyrockets on Impressive Data In Cystic Fibrosismsn.com - March 13 at 6:09 PMAridis stock surges ~35% as lung disease drug AR-501 meets main goal in mid-stage studymsn.com - March 13 at 6:09 PMWhy Aridis Pharmaceuticals Shares Are Soaring Todayfinance.yahoo.com - March 13 at 6:09 PMAridis Shares Rally Premarket on Positive Phase 2a Cystic Fibrosis Study >ARDSmarketwatch.com - March 13 at 8:57 AMAridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patientsfinance.yahoo.com - March 13 at 8:57 AMInterviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Reportfinanznachrichten.de - February 17 at 8:05 AMWhen Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?finance.yahoo.com - February 15 at 7:41 AMIn virtuous cycle, foundation uses drug royalty riches to back new cystic fibrosis drug research in Bay Areafinance.yahoo.com - February 6 at 7:03 PMHere's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock Nowfinance.yahoo.com - February 1 at 4:13 PMAnalysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)markets.businessinsider.com - January 27 at 8:30 AMAridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumoniamsn.com - January 26 at 9:52 AMAridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)finance.yahoo.com - January 25 at 6:34 PMmarketbeat.com - January 25 at 4:11 PMmarketbeat.com - January 24 at 11:16 AMNew Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Updatefinance.yahoo.com - January 17 at 7:06 PMAridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25finance.yahoo.com - December 28 at 1:24 PM(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundationfinance.yahoo.com - December 12 at 5:26 PMAridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundationfinance.yahoo.com - December 12 at 7:32 AM Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 ARDS Media Mentions By Week ARDS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDS News Sentiment▼0.000.32▲Average Medical News Sentiment ARDS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDS Articles This Week▼00▲ARDS Articles Average Week Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GOVX News NEXI News BCEL News SXTP News PHIO News MBIO News ARAV News RNAZ News ONCO News EVOK News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
